Change LocationEn
Choose Your Location
Press Releases
This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Nov 16, 2021Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
- Nov 11, 2021The multi-year impact investment will rebuild homes for at least 50 veterans
- Nov 8, 2021Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Oct 20, 2021Upcoming launch of two interchangeable biosimilar insulin glargine injection options co-developed with Biocon Biologics will help increase access to critical treatment for millions of Americans living with diabetes
- Oct 13, 2021
- Oct 11, 2021Fortune Recognizes Viatris for Expanding Access to Innovative HIV Medicines, Particularly in Low- and Middle-income Countries
- Aug 30, 2021
- Aug 30, 2021
- Aug 9, 2021Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Jul 28, 2021Interchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus® Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes